To the Editor—We are deeply saddened that IDSA did not endorse the 2025 Clinical Practice Guidelines Update for Community-Acquired Pneumonia (CAP) [1, 2]. The update was approved by an equal number of clinical experts appointed by ATS and IDSA, along with 5 nonvoting methodologists and 2 patients after months of careful review of the evidence, discussion, and consensus. We are concerned that for future guideline collaborations with IDSA evaluating antibiotic use, achieving an “appropriate balance,” as suggested by Klompas et al may prove difficult if judgments about antibiotic use are driven primarily by stewardship perspectives.
